MeSH D002177 - candidiasis
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
Events Timeline
Commercial
Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
|---|---|---|---|---|---|---|
| Teva | Voriconazole | Voriconazole |  | 2012-04-06 |  |  |
| Glenmark Pharmaceuticals | Voriconazole | Voriconazole |  | 2015-09-02 |  |  |
| Mylan | Voriconazole | Voriconazole |  | 2010-04-22 |  |  |
| Sandoz | Voriconazole | Voriconazole |  | 2012-05-30 |  |  |
| Merck & Co | Caspofungin | Cancidas (previously Caspofungin MSD) |  | 2001-10-23 |  |  |
| Posaconazole | Noxafil |  | 2005-10-25 | $187 M | Q4/23-Q3/24 | |
| Posaconazole | Posaconazole SP |  | 2005-10-25 |  |  | |
| Pfizer | Anidulafungin | Ecalta |  | 2007-09-20 |  |  |
| Voriconazole | Vfend |  | 2002-03-19 | $187 M | Y2023 | |
| Aurobindo Pharma | Voriconazole | Voriconazole |  | 2016-01-22 |  |  |
| Ajanta Pharma | Voriconazole | Voriconazole |  | 2016-05-24 |  |  |
| Rising Pharmaceuticals | Voriconazole | Voriconazole |  | 2013-05-28 |  |  |
1
2
3
>
Clinical Trials
Historical Success Rate
Phase 1
50%2/4
Phase 2
77%10/13
Phase 3
76%19/25
Approved: 8Overall Success rate: 29%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Drug Name |
|---|---|---|---|---|---|
1
2
>
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use